A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

NCT03219268 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

277

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors
Hematologic Neoplasms
Ovarian Cancer
HER2-positive Advanced Solid Tumors
Non Small Cell Lung Cancer
Small-cell Lung Cancer
Squamous Cell Carcinoma of Head and Neck
Cholangiocarcinoma
Cervical Cancer
TNBC - Triple-Negative Breast Cancer

Interventions

BIOLOGICAL: tebotelimab 1 mg
BIOLOGICAL: tebotelimab 3 mg
BIOLOGICAL: tebotelimab 10 mg
BIOLOGICAL: tebotelimab 30 mg
BIOLOGICAL: tebotelimab 120 mg
BIOLOGICAL: tebotelimab 300 mg
BIOLOGICAL: tebotelimab 400 mg
BIOLOGICAL: tebotelimab 600 mg
BIOLOGICAL: tebotelimab 800 mg
BIOLOGICAL: tebotelimab 1200 mg
BIOLOGICAL: margetuximab

Sponsor

MacroGenics